GS-US-595-6184 (ASCENT-05): A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Objective

Clinical Trial Details

Principal Investigator(s)

Jason Jones, MD

Clinical Trial Categories

• Cancer
• Breast Cancer

Contact

Gynecology Breast Coordinators at 605-322-7536
or gyn.breastresearch@avera.org